Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States.
about
One size does not fit all: why universal decolonization strategies to prevent methicillin-resistant Staphylococcus aureus colonization and infection in adult intensive care units may be inappropriate for neonatal intensive care unitsActive Surveillance and Decolonization Without Isolation Is Effective in Preventing Methicillin-Resistant Staphylococcus aureus Transmission in the Psychiatry UnitsStaphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype.Antimicrobial Susceptibility Profiles of Staphylococcus aureus Isolates Recovered from Humans, Environmental Surfaces, and Companion Animals in Households of Children with Community-Onset Methicillin-Resistant S. aureus InfectionsReduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from AustraliaIn Vitro Antimicrobial Susceptibility of Staphylococcus pseudintermedius Isolates of Human and Animal Origin.Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.Basis for selecting optimum antibiotic regimens for secondary peritonitis.A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations.Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections.Species Diversity and Pheno- and Genotypic Antibiotic Resistance Patterns of Staphylococci Isolated from Retail Ground Meats.Cost savings of universal decolonization to prevent intensive care unit infection: implications of the REDUCE MRSA trial.Biographical Feature: Gary V. Doern, Ph.D.Metabolic Mitigation of Staphylococcus aureus Vancomycin Intermediate-Level Susceptibility.
P2860
Q34123065-2465C7B0-833B-4D5B-AD5E-B37D807EF180Q34802259-10F8F84F-1C73-4516-9BDB-B3995DCAF4F3Q35746096-23DD5900-85A4-41BF-B284-926DD4B3AEA4Q36075860-51FFDDA1-B5B7-4AB1-8446-6A12BEBE4115Q36290502-BA56F4F8-8319-407D-B5BE-68DD60760356Q36834743-5FBF8A5D-D32A-4869-8DB8-3C96008EE48AQ38425879-6E96F288-3CA4-4C86-A2C5-76645D2651C0Q38633450-87397F5C-48AE-4CFE-9634-468563E3DD88Q39623184-6A2440F4-FE3F-47D9-8897-70FFC956961FQ41172934-26D98277-22BF-4A06-8A16-FE06DCDF229AQ41256931-E223D0DA-BA79-45BC-A267-717B5E5C09A6Q41739024-86B0C19F-397A-456E-B38A-8AAEF8C0EF35Q43214930-2499CED7-4FD2-4031-93E7-20116EDE9C16Q50132676-E9982108-1177-4F07-A6E5-047EB497907B
P2860
Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Activities of vancomycin, ceft ...... ce study in the United States.
@en
Activities of vancomycin, ceft ...... ce study in the United States.
@nl
type
label
Activities of vancomycin, ceft ...... ce study in the United States.
@en
Activities of vancomycin, ceft ...... ce study in the United States.
@nl
prefLabel
Activities of vancomycin, ceft ...... ce study in the United States.
@en
Activities of vancomycin, ceft ...... ce study in the United States.
@nl
P2093
P2860
P356
P1476
Activities of vancomycin, ceft ...... ce study in the United States.
@en
P2093
Cassie L Dohrn
Emily K Crispell
Fathollah Riahi
Jennifer S McDanel
Kristopher P Heilmann
Sandra S Richter
Sarah W Satola
P2860
P304
P356
10.1128/AAC.01915-13
P407
P577
2013-11-18T00:00:00Z